Proposed Collection; 60-Day Comment Request; ABCD Study® Audience Feedback Teams (National Institute on Drug Abuse), 67775-67776 [2023-21698]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 189 / Monday, October 2, 2023 / Notices
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Dated: September 27, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
Dated: September 26, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–21740 Filed 9–29–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
BILLING CODE 4140–01–P
Proposed Collection; 60-Day Comment
Request; ABCD Study® Audience
Feedback Teams (National Institute on
Drug Abuse)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
AGENCY:
[FR Doc. 2023–21686 Filed 9–29–23; 8:45 am]
ACTION:
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Research and Development
of Vaccines and Monoclonal Antibodies for
Pandemic Preparedness (ReVAMPP) Centers
for Bunyavirales, Paramyxoviridae and
Picornoviridae (U19 Clinical Trial Not
Allowed).
Date: November 7–9, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Rockville, MD
20892 (Virtual Meeting).
Contact Person: Frank S. De Silva, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, MSC 9823, Rockville, MD
20892–9823, (240) 669–5023, fdesilva@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
VerDate Sep<11>2014
18:41 Sep 29, 2023
Jkt 262001
National Institutes of Health,
HHS.
National Institutes of Health
lotter on DSK11XQN23PROD with NOTICES1
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Notice.
In compliance with the
requirement of the Paperwork
Reduction Act of 1995 to provide
opportunity for public comment on
proposed data collection projects, the
National Institute on Drug Abuse
(NIDA) will publish periodic summaries
of proposed projects to be submitted to
the Office of Management and Budget
(OMB) for review and approval.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 60 days of the date of this
publication.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact: Dr. Kimberly LeBlanc Scientific
Program Manager, Division of
Extramural Research, National Institute
on Drug Abuse, C/O NIH Mail Center/
Dock 11, 3WFN Room 09C77 MSC 6021,
Gaithersburg, MD 20877 (20892 for
USPS), or call non-toll-free number
(301) 827–4102, or Email your request,
including your address, to:
kimberly.leblanc@nih.gov. Formal
requests for additional plans and
instruments must be requested in
writing.
SUPPLEMENTARY INFORMATION: Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires: written
comments and/or suggestions from the
public and affected agencies are invited
to address one or more of the following
points: (1) Whether the proposed
collection of information is necessary
for the proper performance of the
function of the agency, including
whether the information will have
SUMMARY:
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
67775
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
Ways to enhance the quality, utility, and
clarity of the information to be
collected; and (4) Ways to minimizes
the burden of the collection of
information on those who are to
respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
Proposed Collection Title: Adolescent
Brain & Cognitive Development (ABCD)
StudySM—Audience Feedback Teams,
0925 –NEW, exp., date XX/XX/XXXX,
National Institute on Drug Abuse
(NIDA), National Institutes of Health
(NIH).
Need and Use of Information
Collection: The purpose of this
information collection request is to
solicit audience feedback to improve the
data collection process for the
Adolescent Brain Cognitive
Development (ABCD) Study. Started in
2015, the ABCD Study® follows a cohort
of over 10,000 young people from preadolescence into adulthood to
understand how growing brains are
shaped by experiences and biology. To
prepare for each year’s Study data
collection, the National Institute of
Health is collecting audience feedback
on a selection of survey questions and
research protocols. Parents/caregivers
and teens who are the same age as the
study cohort members but who are not
Study participants will review proposed
questions and give feedback on
questions’ clarity and acceptability.
Recommendations from these findings
help the ABCD Study team improve
their protocol for a more-successful data
collection.
Audience feedback activities will
include a mix of asynchronous and
scheduled, live data collection: webbased survey activities, virtual
discussion boards, individual
interviews, and discussions groups.
Assembling a cohort of audience
feedback participants who are familiar
with the ABCD Study and participate in
multiple data collection activities
minimizes the burden required to
familiarize new participants with the
purpose of the Study and the
expectations for audience feedback.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
172.
E:\FR\FM\02OCN1.SGM
02OCN1
67776
Federal Register / Vol. 88, No. 189 / Monday, October 2, 2023 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Type of respondent
Individuals
Individuals
Individuals
Individuals
Individuals
Individuals
Individuals
Individuals
Individuals
Individuals
Individuals
Total annual
burden hour
(Teen Phone Screener) .................................................................
(Teen Assent or Consent) .............................................................
(Teen Web Survey) .......................................................................
(Teen Virtual Group Discussion or Online Bulletin Board) ...........
(Parent/Caregiver Phone Screener) ..............................................
(Parent/Caregiver Permission for Teen Participation) ...................
(Parent/Caregiver Consent) ...........................................................
(Parent/Caregiver Web Survey) ....................................................
(Parent/Caregiver Virtual Interview) ..............................................
(Parent/Caregiver Online Bulletin Board) ......................................
(Parent/Caregiver ‘‘At-Home’’ Materials Review) ..........................
72
36
36
36
72
36
15
15
15
15
15
1
1
2
2
1
1
1
2
1
1
1
5/60
10/60
30/60
1
5/60
5/60
5/60
30/60
30/60
1
15/60
6
6
36
72
6
3
1
15
8
15
4
Total ..........................................................................................................
........................
450
........................
172
Lanette A. Palmquist,
Project Clearance Liaison, National Institute
on Drug Abuse, National Institutes of Health.
[FR Doc. 2023–21698 Filed 9–29–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
lotter on DSK11XQN23PROD with NOTICES1
Average
time per
response
(in hours)
Number of
responses per
respondent
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group,
Community Influences on Health Behavior
Study Section.
Date: October 24–25, 2023.
Time: 9:30 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Washington Plaza Hotel, 10 Thomas
Circle, NW Washington, DC 20005.
Contact Person: Annie Laurie McRee,
DRPH, Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 100,
Bethesda, MD 20892, (301) 827–7396,
mcreeal@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Special
Topics: Neuroimaging Technologies.
VerDate Sep<11>2014
18:41 Sep 29, 2023
Jkt 262001
Date: October 25, 2023.
Time: 9:30 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Mufeng Li, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (240) 507–9155, mufeng.li@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, PAR Panel:
Research on Current Topics in Alzheimer’s
Disease and its Related Dementias.
Date: October 26–27, 2023.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Mei Qin, MD, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5213,
Bethesda, MD 20892, 301–875–2215,
qinmei@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: September 26, 2023.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–21608 Filed 9–29–23; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Infectious Diseases
and Immunology A Integrated Review Group;
HIV Molecular Virology, Cell Biology, and
Drug Development Study Section.
Date: November 13–14, 2023.
Time: 8:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Ritz-Carlton Hotel, 1700 Tysons
Boulevard, McLean, VA 22102.
Contact Person: Kenneth A. Roebuck,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5214,
MSC 7852, Bethesda, MD 20892, (301) 435–
1166, roebuckk@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Nucleic
Acid Therapeutic Delivery (NATD).
Date: November 14–15, 2023.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
E:\FR\FM\02OCN1.SGM
02OCN1
]]>Agencies
[Federal Register Volume 88, Number 189 (Monday, October 2, 2023)]
[Notices]
[Pages 67775-67776]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-21698]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-Day Comment Request; ABCD Study[supreg]
Audience Feedback Teams (National Institute on Drug Abuse)
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In compliance with the requirement of the Paperwork Reduction
Act of 1995 to provide opportunity for public comment on proposed data
collection projects, the National Institute on Drug Abuse (NIDA) will
publish periodic summaries of proposed projects to be submitted to the
Office of Management and Budget (OMB) for review and approval.
DATES: Comments regarding this information collection are best assured
of having their full effect if received within 60 days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data
collection plans and instruments, submit comments in writing, or
request more information on the proposed project, contact: Dr. Kimberly
LeBlanc Scientific Program Manager, Division of Extramural Research,
National Institute on Drug Abuse, C/O NIH Mail Center/Dock 11, 3WFN
Room 09C77 MSC 6021, Gaithersburg, MD 20877 (20892 for USPS), or call
non-toll-free number (301) 827-4102, or Email your request, including
your address, to: [email protected]. Formal requests for
additional plans and instruments must be requested in writing.
SUPPLEMENTARY INFORMATION: Section 3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires: written comments and/or suggestions
from the public and affected agencies are invited to address one or
more of the following points: (1) Whether the proposed collection of
information is necessary for the proper performance of the function of
the agency, including whether the information will have practical
utility; (2) The accuracy of the agency's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) Ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) Ways
to minimizes the burden of the collection of information on those who
are to respond, including the use of appropriate automated, electronic,
mechanical, or other technological collection techniques or other forms
of information technology.
Proposed Collection Title: Adolescent Brain & Cognitive Development
(ABCD) Study\SM\--Audience Feedback Teams, 0925 -NEW, exp., date XX/XX/
XXXX, National Institute on Drug Abuse (NIDA), National Institutes of
Health (NIH).
Need and Use of Information Collection: The purpose of this
information collection request is to solicit audience feedback to
improve the data collection process for the Adolescent Brain Cognitive
Development (ABCD) Study. Started in 2015, the ABCD Study[supreg]
follows a cohort of over 10,000 young people from pre-adolescence into
adulthood to understand how growing brains are shaped by experiences
and biology. To prepare for each year's Study data collection, the
National Institute of Health is collecting audience feedback on a
selection of survey questions and research protocols. Parents/
caregivers and teens who are the same age as the study cohort members
but who are not Study participants will review proposed questions and
give feedback on questions' clarity and acceptability. Recommendations
from these findings help the ABCD Study team improve their protocol for
a more-successful data collection.
Audience feedback activities will include a mix of asynchronous and
scheduled, live data collection: web-based survey activities, virtual
discussion boards, individual interviews, and discussions groups.
Assembling a cohort of audience feedback participants who are familiar
with the ABCD Study and participate in multiple data collection
activities minimizes the burden required to familiarize new
participants with the purpose of the Study and the expectations for
audience feedback.
OMB approval is requested for 3 years. There are no costs to
respondents other than their time. The total estimated annualized
burden hours are 172.
[[Page 67776]]
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average time
Type of respondent Number of responses per per response Total annual
respondents respondent (in hours) burden hour
----------------------------------------------------------------------------------------------------------------
Individuals (Teen Phone Screener)............... 72 1 5/60 6
Individuals (Teen Assent or Consent)............ 36 1 10/60 6
Individuals (Teen Web Survey)................... 36 2 30/60 36
Individuals (Teen Virtual Group Discussion or 36 2 1 72
Online Bulletin Board).........................
Individuals (Parent/Caregiver Phone Screener)... 72 1 5/60 6
Individuals (Parent/Caregiver Permission for 36 1 5/60 3
Teen Participation)............................
Individuals (Parent/Caregiver Consent).......... 15 1 5/60 1
Individuals (Parent/Caregiver Web Survey)....... 15 2 30/60 15
Individuals (Parent/Caregiver Virtual Interview) 15 1 30/60 8
Individuals (Parent/Caregiver Online Bulletin 15 1 1 15
Board).........................................
Individuals (Parent/Caregiver ``At-Home'' 15 1 15/60 4
Materials Review)..............................
---------------------------------------------------------------
Total....................................... .............. 450 .............. 172
----------------------------------------------------------------------------------------------------------------
Lanette A. Palmquist,
Project Clearance Liaison, National Institute on Drug Abuse, National
Institutes of Health.
[FR Doc. 2023-21698 Filed 9-29-23; 8:45 am]
BILLING CODE 4140-01-P
